Inhibition of nuclear factor-κB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy

被引:48
作者
Tamada, S
Nakatani, T
Asai, T
Tashiro, K
Komiya, T
Sumi, T
Okamura, M
Kim, S
Iwao, H
Kishimoto, T
Yamanaka, S
Miura, K
机构
[1] Osaka City Univ, Sch Med, Dept Appl Pharmacol & Therapeut, Abeno Ku, Osaka 5458585, Japan
[2] Osaka City Univ, Dept Urol, Osaka 5458585, Japan
[3] Osaka City Univ, Dept Nephrol, Osaka 5458585, Japan
[4] Osaka City Univ, Dept Pharmacol, Osaka 5458585, Japan
[5] Nara Inst Sci & Technol, Lab Anim Mol Technol, Res & Educ Ctr Genet Informat, Nara, Japan
关键词
nephrotoxicity; immunosuppression; monocyte; macrophage infiltration; tubular injury; interstitial fibrosis; antioxidant; chronic nephropathy; inflammation;
D O I
10.1046/j.1523-1755.2003.00714.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Chronic tacrolimus (FK506) nephrotoxicity is characterized by renal fibrosis with interstitial inflammation. Since nuclear factor-kappaB (NF-kappaB) plays a key role in chronic inflammatory diseases including renal disease, the present study was conducted to elucidate the role of NF-kappaB in the pathogenesis of chronic FK506-induced nephropathy. Methods. FK506 (1 mg/kg/day, SC) was administered daily to rats maintained on low sodium diet for 42 days. Some rats were treated with a putative NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC; 100, 200 mg/kg/day, by gavage). The renal function, renal histology, renal NF-kappaB-DNA binding activity and gene expression profile were examined. Results. FK506 caused a decline in glomerular filtration and induced characteristic renal morphologic changes including arteriolopathy, tubular atrophy and interstitial fibrosis. FK506 markedly activated renal cortical NF-kappaB-DNA binding. PDTC administration inhibited NF-kappaB-DNA binding activity in a dose dependent manner. With higher dose, NF-kappaB-DNA binding activity was decreased to a control level. PDTC had little effect on FK506-induced renal dysfunction. Renal cortical monocyte/macrophage infiltration observed in FK506-treated rats was dramatically suppressed by PDTC. FK506 up-regulated renal cortical gene expression of chemoattractant proteins, monocyte chemoattractant protein-1 (MCP-1) and osteopontin. PDTC significantly blocked MCP-1 gene expression but had no effect on osteopontin gene expression. Tubular atrophy and tubulointerstitial fibrosis, but not arteriolopathy, were significantly attenuated by PDTC. FK506 increased renal mRNA expression of fibrogenic molecules and extracellular matrices that also were attenuated by PDTC treatment. Conclusions. NF-kappaB plays an important role in mediating cortical monocyte/macrophage infiltration and in the pathogenesis of tubular injury and interstitial fibrosis in experimental FK506-induced chronic nephropathy.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 34 条
[1]   FUNCTIONAL AND STRUCTURAL CHARACTERISTICS OF EXPERIMENTAL FK-506 NEPHROTOXICITY [J].
ANDOH, TF ;
BURDMANN, EA ;
LINDSLEY, J ;
HOUGHTON, DC ;
WILLIAM, M ;
BENNETT, WM .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1995, 22 (09) :646-654
[2]   Magnesium supplementation prevents experimental chronic cyclosporine A nephrotoxicity via renin-angiotensin system independent mechanism [J].
Asai, T ;
Nakatani, T ;
Yamanaka, S ;
Tamada, S ;
Kishimoto, T ;
Tashiro, K ;
Nakao, T ;
Okamura, M ;
Kim, S ;
Iwao, H ;
Miura, K .
TRANSPLANTATION, 2002, 74 (06) :784-791
[3]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[4]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[5]   Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response [J].
Beswick, RA ;
Zhang, HF ;
Marable, D ;
Catravas, JD ;
Hill, WD ;
Webb, RC .
HYPERTENSION, 2001, 37 (02) :781-786
[6]   Oxidative stress and nuclear factor-κB activation -: A reassessment of the evidence in the light of recent discoveries [J].
Bowie, A ;
O'Neill, LAJ .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (01) :13-23
[7]   PREVENTION OF EXPERIMENTAL CYCLOSPORINE-INDUCED INTERSTITIAL FIBROSIS BY LOSARTAN AND ENALAPRIL [J].
BURDMANN, EA ;
ANDOH, TF ;
NAST, CC ;
EVAN, A ;
CONNORS, BA ;
COFFMAN, TM ;
LINDSLEY, J ;
BENNETT, WM .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1995, 269 (04) :F491-F499
[8]   CALCINEURIN ACTS IN SYNERGY WITH PMA TO INACTIVATE I-KAPPA-B/MAD3, AN INHIBITOR OF NF-KAPPA-B [J].
FRANTZ, B ;
NORDBY, EC ;
BREN, G ;
STEFFAN, N ;
PAYA, CV ;
KINCAID, RL ;
TOCCI, MJ ;
OKEEFE, SJ ;
ONEILL, EA .
EMBO JOURNAL, 1994, 13 (04) :861-870
[9]   Transcription factor-κB (NF-κB) and renal disease [J].
Guijarro, C ;
Egido, J .
KIDNEY INTERNATIONAL, 2001, 59 (02) :415-424
[10]   Cyclosporine A inhibits tissue factor expression in monocytes/macrophages [J].
Holschermann, H ;
Durfeld, F ;
Maus, U ;
Bierhaus, A ;
Heidinger, K ;
Lohmeyer, J ;
Nawroth, PP ;
Tillmanns, H ;
Haberbosch, W .
BLOOD, 1996, 88 (10) :3837-3845